Proteomic Analysis Reveals that Proteasome Subunit Beta 6 Is Involved in Hypoxia-Induced Pulmonary Vascular Remodeling in Rats

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Wang, Jian ^a,b   Xu, Lei ^a,b   Yun, Xin ^a,b   Yang, Kai ^a,b   Liao, Dongjiang ^a   Tian, Lichun ^a   Jiang, Haiyang ^b   Lu, Wenju ^a,c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; PROTEASOME; PROTEASOME SUBUNIT BETA 1; PROTEASOME SUBUNIT BETA 6; SMALL INTERFERING RNA; UBIQUITIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HYPOXIA; LUNG ALVEOLUS CELL; LUNG FUNCTION; MALE; MUSCLE CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT;

ANIMALS; ANOXIA; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HYPERTENSION, PULMONARY; MALE; MYOCYTES, SMOOTH MUSCLE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOMICS; PULMONARY ARTERY; RATS; RNA, MESSENGER;

RATTUS;

EID: 84879747595     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067942     Document Type: Article

References (44)

1. Tashkin DP, Murray RP, (2009) Smoking cessation in chronic obstructive pulmonary disease. Respir Med 103: 963-974.
2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, et al. (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347-365.
3. Nandi D, Tahiliani P, Kumar A, Chandu D, (2006) The ubiquitin-proteasome system. J Biosci 31: 137-155.
4. Mato AR, Feldman T, Goy A, (2012) Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist 17: 694-707.
5. D'Arcy P, Brnjic S, Olofsson MH, Fryknas M, Lindsten K, et al. (2011) Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 17: 1636-1640.
6. Chauhan D, Bianchi G, Anderson KC, (2008) Targeting the UPS as therapy in multiple myeloma. BMC Biochem 9Suppl 1: S1.
7. Huang H, Liu N, Yang C, Liao S, Guo H, et al. (2012) HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PLoS One 7: e52576.
8. Li HH, Du J, Fan YN, Zhang ML, Liu DP, et al. (2011) The ubiquitin ligase MuRF1 protects against cardiac ischemia/reperfusion injury by its proteasome-dependent degradation of phospho-c-Jun. Am J Pathol 178: 1043-1058.
9. Hedhli N, Depre C, (2010) Proteasome inhibitors and cardiac cell growth. Cardiovasc Res 85: 321-329.
10. Hedhli N, Lizano P, Hong C, Fritzky LF, Dhar SK, et al. (2008) Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload. Am J Physiol Heart Circ Physiol 295: H1385-1393.
11. Friehs I, (2008) Proteasome inhibition in hypertrophied myocardium. Am J Physiol Heart Circ Physiol 295: H1373-1374.
12. Powell SR, Herrmann J, Lerman A, Patterson C, Wang X, (2012) The ubiquitin-proteasome system and cardiovascular disease. Prog Mol Biol Transl Sci 109: 295-346.
13. Ma Y, Chen B, Liu D, Yang Y, Xiong Z, et al. (2011) MG132 treatment attenuates cardiac remodeling and dysfunction following aortic banding in rats via the NF-kappaB/TGFbeta1 pathway. Biochem Pharmacol 81: 1228-1236.
14. de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, et al. (2012) Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol 83: 207-217.
15. Han YH, Park WH, (2010) MG132 as a proteasome inhibitor induces cell growth inhibition and cell death in A549 lung cancer cells via influencing reactive oxygen species and GSH level. Hum Exp Toxicol 29: 607-614.
16. Weiss CH, Budinger GR, Mutlu GM, Jain M, (2010) Proteasomal regulation of pulmonary fibrosis. Proc Am Thorac Soc 7: 77-83.
17. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF, (2009) Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013-1032.
18. Shimoda LA, Wang J, Sylvester JT, (2006) Ca2+ channels and chronic hypoxia. Microcirculation 13: 657-670.
19. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, et al. (2006) Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res 98: 1528-1537.
20. Lu W, Ran P, Zhang D, Peng G, Li B, et al. (2010) Sildenafil inhibits chronically hypoxic up-regulation of canonical transient receptor potential expression in rat pulmonary arterial smooth muscle. Am J Physiol Cell Physiol 298: C114-123.
21. Wang J, Shimoda LA, Sylvester JT, (2004) Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol 286: L848-858.
22. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
23. Pan J, Zhang Q, Wang Y, You M, (2010) 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. PLoS One 5: e13298.
24. Wang J, Jiang Q, Wan L, Yang K, Zhang Y, et al. (2013) Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats. Am J Respir Cell Mol Biol 48: 125-134.
25. Crnkovic S, Hrzenjak A, Marsh LM, Olschewski A, Kwapiszewska G, (2011) Origin of neomuscularized vessels in mice exposed to chronic hypoxia. Respir Physiol Neurobiol 179: 342-345.
26. Slingerland J, Pagano M, (1998) Regulation of the cell cycle by the ubiquitin pathway. Results Probl Cell Differ 22: 133-147.
27. Groll M, Huber R, (2003) Substrate access and processing by the 20S proteasome core particle. Int J Biochem Cell Biol 35: 606-616.
28. Zwickl P, Voges D, Baumeister W, (1999) The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 354: 1501-1511.
29. Tanaka K, (1998) Proteasomes: structure and biology. J Biochem 123: 195-204.
30. Lupas A, Koster AJ, Baumeister W, (1993) Structural features of 26S and 20S proteasomes. Enzyme Protein 47: 252-273.
31. Saeki Y, Tanaka K, (2012) Assembly and function of the proteasome. Methods Mol Biol 832: 315-337.
32. Wang C, Wang J, Zhao L, Wang Y, Liu J, et al. (2008) Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry. J Pharmacol Sci 108: 71-78.
33. Luo Y, Xu DQ, Dong HY, Zhang B, Liu Y, et al. (2013) Tanshinone IIA inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation via Akt/Skp2/p27-associated pathway. PLoS One 8: e56774.
34. Depre C, Wang Q, Yan L, Hedhli N, Peter P, et al. (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114: 1821-1828.
35. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, et al. (2001) Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276: 30057-30063.
36. Divald A, Kivity S, Wang P, Hochhauser E, Roberts B, et al. (2010) Myocardial ischemic preconditioning preserves postischemic function of the 26S proteasome through diminished oxidative damage to 19S regulatory particle subunits. Circ Res 106: 1829-1838.
37. Kim SY, Lee JH, Huh JW, Kim HJ, Park MK, et al. (2012) Bortezomib alleviates experimental pulmonary arterial hypertension. Am J Respir Cell Mol Biol 47: 698-708.
38. Eba S, Hoshikawa Y, Moriguchi T, Mitsuishi Y, Satoh H, et al. (2013) The Nrf2 Activator Oltipraz Attenuates Chronic Hypoxia-Induced Cardiopulmonary Alterations In Mice. Am J Respir Cell Mol Biol.
39. Malhotra D, Thimmulappa R, Vij N, Navas-Acien A, Sussan T, et al. (2009) Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med 180: 1196-1207.
40. Koch A, Steffen J, Kruger E, (2011) TCF11 at the crossroads of oxidative stress and the ubiquitin proteasome system. Cell Cycle 10: 1200-1207.
41. Steffen J, Seeger M, Koch A, Kruger E, (2010) Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell 40: 147-158.
42. You BR, Park WH, (2011) MG132, a proteasome inhibitor-induced calf pulmonary arterial endothelial cell growth and death, are changed by MAPK inhibitors. Drug Chem Toxicol 34: 45-52.
43. Beranova-Giorgianni S (2003) Proteome analysis by two-dimensional gel electrophoresis and mass spectrometry: strengths and limitations. Trends in Analytical Chemistry. 273-281.
44. Shevchenko A, Wilm M, Vorm O, Mann M, (1996) Mass spectrometric sequencing of proteins from silver-stained polyacrylamide gels. Anal Chem 68: 850-858.